KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Common Equity: 2009-2025

Historic Common Equity for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $117.6 million.

  • Rigel Pharmaceuticals' Common Equity rose 903.56% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 903.56%. This contributed to the annual value of $3.3 million for FY2024, which is 111.48% up from last year.
  • Rigel Pharmaceuticals' Common Equity amounted to $117.6 million in Q3 2025, which was up 43.54% from $81.9 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Common Equity's 5-year high stood at $117.6 million during Q3 2025, with a 5-year trough of -$31.8 million in Q3 2023.
  • In the last 3 years, Rigel Pharmaceuticals' Common Equity had a median value of -$24.3 million in 2023 and averaged $2.9 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Common Equity tumbled by 664.62% in 2023, and later skyrocketed by 903.56% in 2025.
  • Rigel Pharmaceuticals' Common Equity (Quarterly) stood at $30.4 million in 2021, then plummeted by 144.83% to -$13.6 million in 2022, then crashed by 110.37% to -$28.6 million in 2023, then surged by 111.48% to $3.3 million in 2024, then soared by 903.56% to $117.6 million in 2025.
  • Its Common Equity stands at $117.6 million for Q3 2025, versus $81.9 million for Q2 2025 and $18.6 million for Q1 2025.